Solid Tumor Cancer Treatment Market By Indication (Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Surgical Procedures) - Growth, Future Prospects, And Competitive Analysis, 2019 - 2027

Industry Outlook

The solid tumor cancer treatment market is set to reach from US$ 121.3 Bn in 2018 to US$ 424.6 Bn by 2027 at a compound annual growth rate (CAGR) of 15.0% during the forecast period from 2019 to 2027. According to the latest statistics presented by the World Health Organization (WHO) in 2018, approximately 9.6 million people are estimated to die due to cancer; they also claim that 30 to 50% of cancer can be prevented with early diagnosis and effective treatment regimen.

Market Synopsis

Solid Tumor Cancer Treatment Market

Get a sample copy for more information

"Hormonal imbalance and unhealthy lifestyle increases the risk of breast cancer in women population worldwide"

Breast cancer is currently leading the indication segment for solid tumor cancer treatment market. The key parameters responsible for its high prevalence rate in women population worldwide are hormonal imbalance during the menstrual cycle of women, unhealthy lifestyle, low or no breast feeding during lifetime. The prevalence rate of lung cancer has seen substantial rise in the last 2 decades owing to increasing number of cigarette smokers globally and significant rise in air pollution.

Solid Tumor Cancer Treatment Market

Get a sample copy for more information

"Availability of generic version at affordable cost makes chemotherapy popular in cancer treatment"

Chemotherapy is presently the largest therapy segment for solid tumor cancer treatment market. The major factor which makes it popular in cancer treatment is its availability of generic version at affordable cost. They are used in combination to gain excellent results in solid tumor cancer treatment. Biologics such as immunotherapy and targeted therapy have gained tremendous popularity in the solid tumor cancer treatment in a span of 2 decades. Minimal side effects, excellent therapeutic efficacy and favorable reimbursement scenario drives its market growth for treatment of solid tumor cancers.

Solid Tumor Cancer Treatment Market

Get a sample copy for more information

"Rising prevalence of cancer and domicile of key players together drive the market growth in North America region"

North America is currently representing 33.6% market share in the regional segment for solid tumor cancer treatment market. The primary factor responsible for its market dominance is rising prevalence of cancer, According to the latest statistics brought forward by the Center for Disease Control and Prevention (CDC), in a span of 10 years from 2010-2020 in the U.S. the number of new cancer cases will rise by 24% in men amounting to 1million cases annually and 21% in women approximately 900,000 cases per year. Domicile of major players such as AstraZeneca, Merck & Co., Inc., Amgen, Inc. etc. will further bolster the market growth in the region. Europe accounts for 30.2% market share on account of supportive regulatory environment provided by European Medical Agency (EMA) for the development and sale of pharmacological medicines used in solid tumor cancer treatment. Favorable reimbursement scenario further consolidates the market growth. Asia Pacific with a share of 19.5% will be registering good growth during the forecast period owing to the rising public health awareness regarding cancer and its treatment and developing healthcare infrastructure.

Solid Tumor Cancer Treatment Market

Historical & Forecast Period

This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market segmentation comprises of by indication, therapy and geography.

Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Billion

 By Indication (2017–2027; US$ Bn)
 • Breast Cancer
 • Cervical Cancer
 • Colorectal Cancer
 • Lung Cancer
 • Prostate Cancer
 • Others

 By Therapy (2017–2027; US$ Bn)
 • Chemotherapy
 • Targeted Therapy
 • Immunotherapy
 • Hormone Therapy
 • Surgical Procedures

 Geography Segment (2017–2027; US$ Bn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of MEA)

Pharmaceutical companies spearheading the solid tumor cancer treatment market are AstraZeneca, Plc., Amgen, Inc., B. Braun Melsungen AG, Bristol Myers Squibb & Company, Eli Lilly & Company, F.Hoffman La-Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc. and Olympus Medical Systems.

Key questions answered in this report

  • Which are the major biopharmaceutical companies actively providing medicines for the treatment of solid tumor cancer?
  • Which organic and inorganic market growth strategies are being considered for performing market assessment?
  • What is the disease etiology and prevalence rate of common types of cancer worldwide?
  • What does biologics comprise of and what will be its CAGR during the growth period?
  • What is the market size in developed regions such as North America and Europe?
Choose License Type
Budget Buying
Executive Summary - Brief Global Market Size - Current & Forecast
Regional Market Size - North America
Country Market Size - US
Company Profile – 1
Trusted By
Published Date:  Aug 2019
Category:  Pharmaceuticals
Report ID:   59822
Report Format:   PDF
Pages:   120
Rating:    4.2 (69)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support